A

Amgen

Makes biotech medicines for serious illnesses

Principal Machine Learning Engineer

Full-TimeUpdated on 10/24/2026
No salary listed
Expert
Bachelor's, Master's
Hyderabad, Telangana, India
In Person
AI & Machine LearningApplied Machine Learning

About the job

Requirements
  • Overall career span of 10–12+ years building production-grade technology solutions, including 3–5 years of hands-on experience in AI/ML and enterprise software.
  • Strong command of machine-learning algorithms, including regression, tree-based ensembles, clustering, dimensionality reduction, time-series models, deep-learning architectures such as CNNs, RNNs and transformers, and modern LLM/RAG techniques, with judgment to select, tune and operationalize methods for business problems.
  • Proven track record selecting and integrating AI SaaS/PaaS offerings and building custom ML services at scale.
  • Expert knowledge of generative AI tooling, including vector databases, RAG pipelines, prompt-engineering DSLs and agent frameworks such as LangChain, LangGraph and Semantic Kernel.
  • Proficiency in Python and Java; containerization with Docker and Kubernetes; cloud platforms such as AWS, Azure or GCP; and modern DevOps/MLOps tools such as GitHub Actions, Bedrock and SageMaker Pipelines.
  • Ability to evaluate technical and business trade-offs, including cost, scalability, risk, ROI and time-to-value, and present recommendations to senior stakeholders.
  • Stakeholder management and technical leadership skills, including translating complex concepts into concise, outcome-oriented narratives and influencing decisions across engineering, product and business teams.
  • Master’s degree with 10–12+ years of experience in Computer Science, IT or a related field, or Bachelor’s degree with 12–14+ years of experience in Computer Science, IT or a related field.
  • Analytical and troubleshooting skills.
  • Verbal and written communication skills.
  • Ability to work effectively with global, virtual teams.
  • Ability to manage multiple priorities successfully.
  • Presentation and public-speaking skills.
Responsibilities
  • Own enterprise AI/ML architecture, engineering standards, APIs, guardrails and reusable patterns across cloud and on-premises environments.
  • Build production ML and generative-AI solutions and lightweight applications that deliver business-ready insights with attention to performance, reliability and usability.
  • Build end-to-end ML pipelines for data ingestion, feature engineering, training, hyperparameter optimization, evaluation, registration and automated promotion using Kubeflow, SageMaker Pipelines, OpenAI SDK or equivalent MLOps stacks.
  • Build and maintain full-stack AI applications by integrating model services with lightweight user-interface components, workflow engines or business-logic layers to deliver insights with sub-second latency.
  • Establish observability and operational excellence through service-level objectives, safe deployment patterns such as blue-green/canary deployments, shadow deployments and rollbacks, incident runbooks and production monitoring.
  • Lead rigorous offline and online evaluation, A/B testing, drift detection and automated retraining.
  • Architect LLM/RAG solutions with prompt management, grounding strategies, safety guardrails, evaluation frameworks and optimized inference patterns.
  • Enforce data quality, lineage and responsible AI practices by maintaining model and data cards, privacy controls, traceability, auditability and human oversight where required.
  • Contribute reusable ML/generative-AI platform components, including feature stores, model registries, experiment-tracking libraries, evaluation assets and deployment templates, and promote best practices that raise engineering velocity across teams.
  • Perform exploratory data analysis and feature ideation on complex, high-dimensional datasets to inform algorithm selection and ensure model robustness.
  • Prototype and benchmark new algorithms, advise on scalability trade-offs and production readiness, and co-own model-performance KPIs.
  • Translate domain needs across R&D, Manufacturing and Commercial functions into technical roadmaps; influence solution design, mentor engineers and data scientists, and communicate trade-offs to senior stakeholders.
  • Lead architecture reviews and technical governance for enterprise AI initiatives, make build-versus-buy decisions, and ensure alignment with security, compliance and platform standards.
  • Drive adoption in regulated environments by embedding validation readiness, explainability, risk controls and scalable operating practices into AI solutions from design through production.
Desired Qualifications
  • Experience in the biotechnology or pharmaceutical industry.
  • Exposure to Value and Access, market access, payer, commercial analytics or related healthcare business domains.
  • Experience delivering AI/ML solutions in regulated environments, with familiarity in validation, auditability, explainability and risk controls.
  • Published thought leadership or conference talks on enterprise generative-AI adoption.
  • Master’s degree in Computer Science and/or Data Science.
  • Familiarity with Agile methodologies and the Scaled Agile Framework (SAFe) for project delivery.
  • Certifications on generative-AI/ML platforms such as AWS AI, Azure AI Engineer or Google Cloud ML.
  • Initiative and self-motivation.
  • Ability to learn quickly and to be organized and detail-oriented.
  • Team orientation and focus on achieving team goals.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.